Image For Activity Cover
2022 World Conference on Lung Cancer (Posters)
Conference | 2022
What's Included
P1.01-01. Comparison between Protein and Autoantibody Biomarkers for the Early Detection of Lung Cancer
Faculty:
- Xiaoshuang Feng, France

P1.02-02. Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries
Faculty:
- Milena Cavic, Serbia

P1.02-03. Budget Impact Analysis of Volume CT Lung Cancer Screening Based on NELSON Study Outcomes in Europe
Faculty:
- Xuanqi Pan, Netherlands

P1.02-04. Spatial Access to Lung Screening in British Columbia, Canada
Faculty:
- Stephen Lam, Canada

P1.03-01. Do We Follow Incidental Lung Nodules Appropriately? A Retrospective Study
Faculty:
- Jasleen Pannu, United States

P1.04-01. Risk Stratification for Personalised Screening Intervals: Performance of PLCOm2012NoRace at Second Round of Manchester LHC
Faculty:
- Patrick Bradley, United Kingdom

P1.04-02. Optimizing Screening Frequency and Interval Using a Deep Learning Algorithm
Faculty:
- Stephen Lam, Canada

P1.04-03. Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals
Faculty:
- Giulia Veronesi, Italy

P1.05-01. Phase II Study of ctDNA Directed Consolidation Durvalumab After Induction and Concurrent Durvalumab with SABR for Stage I NSCLC
Faculty:
- Islam Mohamed, Canada

P1.05-02. Mutations in CREBBP are Associated with Local Failure after Lung Stereotactic Body Radiation Therapy
Faculty:
- Victor Ng, United States

P1.06-01. Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study
Faculty:
- Toon Van Der Gronde, United States

P1.07-01. Early Detection Plus Timely Surgery Remains the Standard despite Advances in Immunotherapy
Faculty:
- Emanuela Taioli, United States

P1.07-02. Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study
Faculty:
- Juan Carlos Laguna, Spain

P1.08-01. Updated Costs and Survival Expectations for Stage IV Lung Cancer in Australia
Faculty:
- Preston Ngo, Australia

P1.09-01. The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey
Faculty:
- Pauline Frank, Msc, Switzerland

P1.09-02. Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC
Faculty:
- Xiuning Le, United States

P1.09-03. Multidisciplinary Thoracic Tumours Board Survey in Spain
Faculty:
- Bartomeu Massutí, Spain

P1.10-01. Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients
Faculty:
- Aarthi Gopinathan, United Kingdom

P1.10-02. ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation
Faculty:
- Fiona Hegi-Johnson, Australia

P1.10-03. A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer
Faculty:
- Gerard Walls, United Kingdom

P1.10-04. Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era
Faculty:
- Neal Mccall, United States

P1.11-01. Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
Faculty:
- Hye Ryun Kim, South Korea

P1.11-02. Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C
Faculty:
- Baohui Han, China

P1.12-01. Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact
Faculty:
- Andrew Ciupek, United States

P1.12-02. The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort
Faculty:
- Bea Brown, Australia

P1.12-03. Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19
Faculty:
- Yusuf Kahya, Turkey

P1.12-04. The FLARE Score and Circulating Neutrophils Are Associated with Poor Covid-19 Outcomes in Patients with Thoracic Cancers
Faculty:
- Laura Mezquita, Spain

P1.12-05. Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st Wave)
Faculty:
- Yu Zhi Zhang, United Kingdom

P1.13-01. Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma
Faculty:
- Luigi Ventura, United Kingdom

P1.13-02. Quantitative Assessment Using MR in Malignant Pleural Mesothelioma
Faculty:
- Ritu Gill, United States

P1.14-01. Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing
Faculty:
- Alexander Laure, Switzerland

P1.14-03. Characterization of Tumour Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumours
Faculty:
- Haojie Si, China

P1.14-04. Silencing ADAR1 Abrogates Mesothelioma Tumourigenicity
Faculty:
- Robert Kratzke, United States

P1.14-05. TROP2 Expression and SN38 Antitumour Activity in Malignant Pleural Mesothelioma Cells
Faculty:
- Luca Hegedüs, Germany

P1.15-01. Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics
Faculty:
- Alberto Traverso, Netherlands

P1.15-02. Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
Faculty:
- Claudia Proto, Italy

P1.15-03. Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
Faculty:
- Federica Pecci, United States

P1.15-04. Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
Faculty:
- Giulia Mazzaschi, Italy

P1.15-05. Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
Faculty:
- Martin Reck, Germany

P1.15-06. Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis
Faculty:
- Martina Lorenzi, Italy

P1.15-07. Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Faculty:
- Melina Marmarelis, United States

P1.15-08. Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer
Faculty:
- Michael Boyer, Australia

P1.15-10. Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada
Faculty:
- Sze Wh Samuel Chan, Canada

P1.15-11. Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
Faculty:
- Myung-Ju Ahn, South Korea

P1.15-12. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
Faculty:
- Saadettin Kilickap, Turkey

P1.15-13. Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer
Faculty:
- Satoshi Muto, Japan

P1.16-01. Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Byoung Chul Cho, South Korea

P1.16-02. Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
Faculty:
- Laura Mezquita, Spain

P1.16-03. Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
Faculty:
- Luis Raez, United States

P1.16-04. Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
Faculty:
- Niels Reinmuth, Germany

P2.01-01. Association Between Clinical Outcomes and Local Treatment in Stage IV Non-small Cell Lung Cancer Patients With Single Extrathoracic Metastasis
Faculty:
- Seung Joon Kim, South Korea

P2.01-02. Delivery of Concurrent Extracranial Stereotactic Body Radiotherapy With Osimertinib for Oligoprogressive EGFR Mutated Stage IV NSCLC
Faculty:
- Eyal Tsur, Israel

P2.02-01. Value of Albumin-to-Globulin Ratio for Survival Prediction in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy
Faculty:
- Chaichana Chantharakhit, Thailand

P2.02-02. A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
Faculty:
- Ralph Millett, United States

P2.02-03. A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
Faculty:
- Saurav Verma, India

P2.03-01. Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with
Faculty:
- 89 Zr-Durvalumab (MEDI4736) PET/CT

P2.04-01. Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries
Faculty:
- Andreja Sajnic, Croatia

P2.04-02. Psychosocial Burdens in Cancer Caregivership, an Updated Overview
Faculty:
- Csaba Dégi, Romania

P2.04-03. Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumours and their Care-Givers
Faculty:
- Paolo Bironzo, Italy

P2.04-04. Is Opioid Use in the Management of Stage III Non-Small Cell Lung Cancer Patients Necessary?
Faculty:
- Ulrike Gorgens, United States

P2.05-01. The Effect of Treadmill Training on Cardiopulmonary, Health-related Quality of Life in Lung Cancer with Lobectomy
Faculty:
- Kyung-Lim Joa, South Korea

P2.06-01. Skip Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer Has Similar Survival to N0 Disease: Need for a change in the pN sub-classification?
Faculty:
- Ismail Sarbay, Turkey

P2.07-01. Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples
Faculty:
- Bahar Rahsepar, United States

P2.07-02. RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
Faculty:
- Susana Hernandez, Spain

P2.08-01. Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers
Faculty:
- Andrew Ciupek, United States

P2.08-02. Burning the Candle at Both Ends-Sleep Quality Before and After Chemotherapy in Lung Cancer Patients - A Systematic Review and Meta-Analysis
Faculty:
- Andrew Jeklin, Australia

P2.08-03. Patient Reported Lung Cancer Care Team Satisfaction and Treatment Dynamics, Based on the Online MyHealthTeams Survey
Faculty:
- Dianna Cronin, United States

P2.08-04. Patient Reported Impact of Lung Cancer Symptoms and Treatment on Mental Health and Quality of Life, Based on the Online MyHealthTeams Survey
Faculty:
- Dianna Cronin, United States

P2.08-05. Lung Cancer Patients’ Willingness to Attend a Screening Appointment or Lung Health Check: Insights from a Global Patient Experience Survey
Faculty:
- Jackie Fenemore, United Kingdom

P2.08-06. Patient Involvement in Decision-Making around Their Treatment and Care: Findings from a Global Patient Experience Survey
Faculty:
- Jackie Fenemore, United Kingdom

P2.08-07. The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma
Faculty:
- Dusty Donaldson, United States

P2.08-08. Where Have All the Lung Cancer Support Groups Gone?
Faculty:
- Maureen Rigney, United States

P2.08-09. Adaptation of Empathic Communication Skills Training for Oncology Care Providers to Reduce Lung Cancer Stigma
Faculty:
- Jamie Ostroff, United States

P2.09-01. MRI-based Radiomic Signature to Predict Pathologic High-grade Pattern in Lung Adenocarcinoma
Faculty:
- Harim Kim, South Korea

P2.09-02. Clinical Nodal (cN) Category Is Independently Prognostic for Overall Survival in Unresectable Advanced/Metastatic Lung Cancer
Faculty:
- Navneet Singh, India

P2.09-03. A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1
Faculty:
- Ren Yuan, Canada

P2.10-01. Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts
Faculty:
- C. Allison Stewart, United States

P2.10-02. EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer
Faculty:
- Balazs Halmos, United States

P2.10-04. Immunologic Subtype of Small Cell Lung Carcinoma Dictates Susceptibility to NK Cell-Mediated Cytotoxicity
Faculty:
- Navin Mahadevan, United States

P2.10-05. Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC
Faculty:
- Vito Longo, Italy

P2.12-01. Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)
Faculty:
- Angelo Porciuncula, United States

P2.12-02. Immune-Cell Distribution Between Tumour Edge and Center Affects Lung Cancer Aggressiveness - Multiplex Immunofluorescence
Faculty:
- Takashi Eguchi, Japan

P2.12-03. External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
Faculty:
- Laurent Dercle, United States

P2.12-04. The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)
Faculty:
- Youjin Oh, United States

P2.12-05. Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression
Faculty:
- Thomas Marron, United States

P2.13-01. Low EV miR-30c Levels as Biomarker of Increased Tumour Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC
Faculty:
- Diego de Miguel Perez, United States

P2.13-02. Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)
Faculty:
- Kevin Chua, Singapore

P2.13-03. Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
Faculty:
- Per Hydbring, Sweden

P2.14-01. Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC
Faculty:
- Khaled Tolba, United States

P2.14-02. TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Faculty:
- Lorenza Landi, Italy

P2.14-03. Restored Ubiquitination and Degradation of Exon 14 Skipped MET with Proteolysis Targeting Chimeras
Faculty:
- Aaron Mansfield, United States

P2.14-04. Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches
Faculty:
- Sara Hijazo-Pechero, Spain

Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Contains (91)
P1.01-01. Comparison between Protein and Autoantibody Biomarkers for the Early Detection of Lung Cancer
P1.02-02. Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries
P1.02-03. Budget Impact Analysis of Volume CT Lung Cancer Screening Based on NELSON Study Outcomes in Europe
P1.02-04. Spatial Access to Lung Screening in British Columbia, Canada
P1.03-01. Do We Follow Incidental Lung Nodules Appropriately? A Retrospective Study
P1.04-01. Risk Stratification for Personalised Screening Intervals: Performance of PLCOm2012NoRace at Second Round of Manchester LHC
P1.04-02. Optimizing Screening Frequency and Interval Using a Deep Learning Algorithm
P1.04-03. Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals
P1.05-01. Phase II Study of ctDNA Directed Consolidation Durvalumab After Induction and Concurrent Durvalumab with SABR for Stage I NSCLC
P1.05-02. Mutations in CREBBP are Associated with Local Failure after Lung Stereotactic Body Radiation Therapy
P1.06-01. Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study
P1.07-01. Early Detection Plus Timely Surgery Remains the Standard despite Advances in Immunotherapy
P1.07-02. Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study
P1.08-01. Updated Costs and Survival Expectations for Stage IV Lung Cancer in Australia
P1.09-01. The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey
P1.09-02. Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC
P1.09-03. Multidisciplinary Thoracic Tumours Board Survey in Spain
P1.10-01. Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients
P1.10-02. ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation
P1.10-03. A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer
P1.10-04. Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era
P1.11-01. Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
P1.11-02. Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C
P1.12-01. Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact
P1.12-02. The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort
P1.12-03. Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19
P1.12-04. The FLARE Score and Circulating Neutrophils Are Associated with Poor Covid-19 Outcomes in Patients with Thoracic Cancers
P1.12-05. Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st Wave)
P1.13-01. Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma
P1.13-02. Quantitative Assessment Using MR in Malignant Pleural Mesothelioma
P1.14-01. Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing
P1.14-03. Characterization of Tumour Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumours
P1.14-04. Silencing ADAR1 Abrogates Mesothelioma Tumourigenicity
P1.14-05. TROP2 Expression and SN38 Antitumour Activity in Malignant Pleural Mesothelioma Cells
P1.15-01. Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics
P1.15-02. Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
P1.15-03. Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity
P1.15-04. Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
P1.15-05. Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)
P1.15-06. Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis
P1.15-07. Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
P1.15-08. Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer
P1.15-10. Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada
P1.15-11. Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study
P1.15-12. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
P1.15-13. Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer
P1.16-01. Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
P1.16-02. Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
P1.16-03. Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
P1.16-04. Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
P2.01-01. Association Between Clinical Outcomes and Local Treatment in Stage IV Non-small Cell Lung Cancer Patients With Single Extrathoracic Metastasis
P2.01-02. Delivery of Concurrent Extracranial Stereotactic Body Radiotherapy With Osimertinib for Oligoprogressive EGFR Mutated Stage IV NSCLC
P2.02-01. Value of Albumin-to-Globulin Ratio for Survival Prediction in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy
P2.02-02. A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
P2.02-03. A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
P2.03-01. Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with
P2.04-01. Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries
P2.04-02. Psychosocial Burdens in Cancer Caregivership, an Updated Overview
P2.04-03. Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumours and their Care-Givers
P2.05-01. The Effect of Treadmill Training on Cardiopulmonary, Health-related Quality of Life in Lung Cancer with Lobectomy
P2.06-01. Skip Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer Has Similar Survival to N0 Disease: Need for a change in the pN sub-classification?
P2.07-01. Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples
P2.07-02. RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
P2.08-01. Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers
P2.08-02. Burning the Candle at Both Ends-Sleep Quality Before and After Chemotherapy in Lung Cancer Patients - A Systematic Review and Meta-Analysis
P2.08-03. Patient Reported Lung Cancer Care Team Satisfaction and Treatment Dynamics, Based on the Online MyHealthTeams Survey
P2.08-04. Patient Reported Impact of Lung Cancer Symptoms and Treatment on Mental Health and Quality of Life, Based on the Online MyHealthTeams Survey
P2.08-05. Lung Cancer Patients’ Willingness to Attend a Screening Appointment or Lung Health Check: Insights from a Global Patient Experience Survey
P2.08-06. Patient Involvement in Decision-Making around Their Treatment and Care: Findings from a Global Patient Experience Survey
P2.08-07. The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma
P2.08-08. Where Have All the Lung Cancer Support Groups Gone?
P2.08-09. Adaptation of Empathic Communication Skills Training for Oncology Care Providers to Reduce Lung Cancer Stigma
P2.09-01. MRI-based Radiomic Signature to Predict Pathologic High-grade Pattern in Lung Adenocarcinoma
P2.09-02. Clinical Nodal (cN) Category Is Independently Prognostic for Overall Survival in Unresectable Advanced/Metastatic Lung Cancer
P2.09-03. A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1
P2.10-01. Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts
P2.10-02. EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer
P2.10-04. Immunologic Subtype of Small Cell Lung Carcinoma Dictates Susceptibility to NK Cell-Mediated Cytotoxicity
P2.10-05. Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC
P2.12-01. Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)
P2.12-02. Immune-Cell Distribution Between Tumour Edge and Center Affects Lung Cancer Aggressiveness - Multiplex Immunofluorescence
P2.12-03. External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
P2.12-04. The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)
P2.12-05. Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression
P2.13-01. Low EV miR-30c Levels as Biomarker of Increased Tumour Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC
P2.13-02. Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)
P2.13-03. Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
P2.14-01. Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC
P2.14-02. TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
P2.14-03. Restored Ubiquitination and Degradation of Exon 14 Skipped MET with Proteolysis Targeting Chimeras
P2.14-04. Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches
Powered By